green
et
al
sion
fact
compel
mani
author
challeng
exist
vaccin
practic
articl
intend
establish
new
vaccin
standard
dog
use
templat
nation
canin
vaccin
protocol
nevertheless
chang
wind
revis
recommend
canin
vaccin
anticip
materi
present
articl
serv
guid
clinician
will
consid
propos
canin
vaccin
recommend
appli
individu
patient
tabl
repres
summari
inform
present
articl
realli
necessari
revis
vaccin
recommend
dog
mani
would
challeng
premis
vaccin
practic
last
year
fact
work
well
canin
distemp
canin
parvoviru
canin
rabi
virtual
nonexist
among
vaccin
yet
despit
obviou
success
attribut
companion
anim
vaccin
veterinarian
must
will
least
review
revis
vaccin
practic
standard
new
vaccin
introduc
new
vaccin
technolog
develop
object
quit
simpli
administ
appropri
vaccin
appropri
stage
life
best
product
avail
occur
complac
regiment
respect
select
administr
vaccin
yet
happen
demand
among
veterinarian
vaccin
simpl
administ
timesav
led
longterm
widespread
use
polyval
vaccin
twentyf
year
ago
commonli
use
polyval
product
contain
three
vaccin
distemperhepatitisleptospirosi
today
product
contain
eight
vaccin
per
dose
routin
administ
dog
furthermor
polyval
vaccin
routin
administ
annual
seemingli
littl
regard
actual
risk
infect
disturb
trend
annual
administr
polyval
vaccin
impli
vaccin
antigen
whether
bacteri
viral
origin
polyval
product
induc
degre
immun
durat
everi
patient
immunolog
irrat
depend
vaccin
base
result
control
challeng
studi
dog
deriv
protect
immun
persist
littl
month
long
year
conveni
rather
scienc
seem
drive
forc
behind
convent
recommend
list
vaccin
label
product
insert
even
rule
us
depart
agricultur
manufactur
new
veterinari
biolog
agent
must
document
durat
immun
list
label
rule
appli
recommend
infecti
canin
hepat
uncommon
unit
state
consid
low
absent
preval
risk
hepat
blueey
reaction
fact
crossprotect
cavl
use
vaccin
contain
antigen
recommend
use
routin
vaccin
protocol
recommend
demonstr
crossprotect
canin
hepat
cavl
one
agent
known
associ
infecti
tracheobronch
usual
combin
cdv
crv
vaccin
current
product
avail
monoval
vaccin
adult
dog
challeng
year
mlv
vaccin
found
protect
virul
cavl
option
lyme
diseas
limit
region
preval
recommend
use
limit
dog
known
high
risk
exposur
option
lyme
diseas
limit
region
preval
recommend
use
strictli
limit
dog
known
high
risk
exposur
author
recommend
recombin
lyme
vaccin
kill
bacterin
reason
safeti
fewer
advers
reaction
requir
mlv
vaccin
avail
state
local
statut
govern
frequenc
administr
product
label
iyear
rabi
rabi
iyear
vaccin
gener
administ
initi
dose
follow
year
later
administr
rabi
vaccin
state
local
statut
may
dictat
otherwis
requir
state
local
statut
govern
frequenc
administr
product
label
rabi
statut
vari
throughout
unit
state
rabi
iyear
vaccin
gener
administ
initi
dose
follow
year
later
administr
rabi
vaccin
state
local
statut
may
dictat
otherwis
vaccin
licens
like
chang
annual
booster
recommend
stipul
manufactur
import
understand
manufactur
mandat
establish
full
durat
immun
document
claim
studi
establish
maximum
durat
immun
would
meet
usda
guidelin
econom
feasibl
recommend
virtual
canin
vaccin
administ
annual
adult
dog
embrac
veterinari
profess
mani
year
interestingli
howev
vaccin
administ
dog
today
scientif
studi
establish
durat
immun
vaccin
efficaci
studi
vaccin
use
today
challeng
vaccin
week
last
inocul
paradigm
adult
dog
cat
requir
annual
booster
commonli
administ
vaccin
challeng
simpli
continu
arbitrarili
administ
vaccin
without
regard
number
type
vaccin
antigen
product
without
realist
consider
risk
infect
face
individu
modifi
live
viru
mlv
vaccin
effect
protect
dog
canin
distemp
inactiv
whole
viral
vaccin
effect
howev
vector
recombin
vaccin
current
avail
puppi
distemp
vaccin
perform
interv
earliest
inocul
given
puppi
week
age
distemp
vaccin
use
north
america
today
overcom
matern
immun
time
puppi
week
age
vaccin
puppi
usual
continu
reach
week
age
dog
older
week
age
time
present
initi
vaccin
receiv
least
two
canin
distemp
viru
cdv
inocul
week
apart
minimum
durat
immun
determin
challeng
attenu
mlv
cdv
least
year
vaccin
use
rockport
strain
cdv
although
vaccin
use
onderstepoort
strain
least
year
recombin
cdv
vaccin
canari
poxvector
vaccin
express
distemp
fusion
hemagglutinin
glycoprotein
dog
receiv
vaccin
must
receiv
least
two
dose
initi
report
durat
immun
least
month
annual
booster
vaccin
recommend
use
product
combin
distempermeasl
vaccin
still
avail
stage
life
administr
mlv
cdv
vaccin
expect
fail
measl
vaccin
capabl
caus
heterotyp
immun
respons
presenc
high
concentr
matern
deriv
distemp
antibodi
veterinarian
still
recommend
administr
covmeasl
viru
vaccin
puppi
week
age
product
use
femal
puppi
week
age
matern
antibodi
cov
measl
may
develop
antibodi
would
transfer
subsequ
offspr
level
could
interfer
measl
cov
vaccin
puppi
therefor
antibodi
would
interfer
protect
effect
mvcov
vaccin
heterotyp
mv
would
provid
earli
protect
cov
administr
combin
mlv
coymeasl
viru
vaccin
limit
puppi
nurs
statu
unknown
like
face
cov
exposur
puppi
measl
vaccin
indic
dog
week
age
vaccin
canin
adenoviru
infect
caus
infecti
canin
hepat
ich
usual
done
combin
distemp
diseas
begin
puppi
week
age
attenu
mlv
adenoviru
vaccin
gener
use
unit
state
abil
produc
superior
immun
respons
inactiv
product
still
avail
us
market
mani
countri
vaccin
ich
reduc
preval
diseas
widespread
outbreak
isol
case
still
occur
vaccin
puppi
delay
incomplet
shed
modifi
virus
high
stabil
outsid
host
respons
inadvert
immun
mani
dog
vaccin
ich
contain
either
kill
homolog
canin
adenovirusl
cavl
close
relat
respiratori
isol
mlv
canin
former
gener
shed
urin
latter
shed
upper
respiratori
secret
howev
amount
shed
vari
individu
product
anoth
side
effect
attenu
cavl
vaccin
abil
produc
anterior
uveiti
corneal
edema
opacif
blue
eye
small
percentag
dog
document
vaccin
caus
uveiti
although
inactiv
vaccin
produc
lesser
serolog
respons
shed
host
caus
anterior
uveiti
absenc
exposur
virul
viru
period
booster
inactiv
adenoviru
vaccin
might
requir
sustain
immun
halflif
matern
antibodi
ich
similar
coy
approxim
day
time
puppi
reach
week
age
matern
antibodi
usual
detect
vaccin
ich
thu
typic
combin
cdv
initi
vaccin
administ
puppi
week
age
everi
week
reach
week
age
although
booster
inocul
recommend
annual
adult
dog
challeng
studi
demonstr
durat
immun
least
year
attenu
use
vaccin
antigen
durat
immun
kill
vaccin
mlv
intranas
known
mlv
shown
immun
dog
respiratori
hepat
cavl
adenovirus
consid
risk
associ
administr
cavl
dog
use
mlv
cavl
vaccin
recommend
infecti
tracheobronch
itb
kennel
cough
complex
clinic
infect
caus
number
respiratori
pathogen
infect
dog
alon
combin
caus
virus
includ
distemp
cdv
adenoviru
parainfluenza
viru
herpesviru
reoviru
bordetella
bronchiseptica
recogn
bacteri
pathogen
secretori
antibodi
serum
provid
protect
infect
upper
respiratori
mucos
surfac
parenter
intranas
vaccin
exist
parainfluenza
viru
b
bronchiseptica
although
protect
agent
develop
routin
vaccin
program
vaccin
agent
herpesviru
reoviru
avail
durat
immun
produc
mani
vaccin
respiratori
pathogen
well
establish
label
product
recommend
annual
booster
unlik
dog
deriv
signific
immun
beyond
month
subsequ
intranas
vaccin
intranas
b
bronchiseptica
vaccin
durat
immun
may
actual
less
month
perform
parenter
administ
infecti
tracheobronch
itb
vaccin
quit
differ
intranas
topic
administ
vaccin
parenter
administ
vaccin
itb
provid
durat
immun
month
longer
depend
antigen
known
whether
parenter
administr
itb
antigen
culmin
develop
effect
local
upper
respiratori
tract
immun
respons
matern
antibodi
interfer
parenter
administ
vaccin
hand
vaccin
label
intranas
topic
administr
administ
puppi
young
week
age
depend
product
seem
induc
local
immun
respons
interf
matern
antibodi
rel
rapid
onset
day
note
although
pneumonia
caus
virul
b
bronchiseptica
canin
vaccin
report
immunocompromis
human
be
inadvert
nasal
ocular
exposur
avirul
live
canin
b
bronchiseptica
vaccin
known
caus
clinic
ill
symptom
human
be
vaccin
separ
parenter
product
usual
begin
puppi
week
age
safe
pregnant
anim
anim
receiv
least
two
dose
week
apart
complet
protect
expect
week
second
vaccin
intranas
parainfluenza
bordetella
vaccin
may
protect
within
hour
use
thu
use
help
prevent
ill
outbreak
kennel
pet
hospit
boardingp
vaccin
respiratori
pathogen
induc
steril
immun
word
vaccin
anim
challeng
expect
becom
infect
may
exhibit
mild
short
clinic
ill
clinic
sign
upper
respiratori
infect
may
develop
subsequ
intranas
administr
vaccin
sign
gener
mild
unnotic
canin
vaccin
avail
inactiv
mlv
product
recombin
vaccin
current
avail
develop
mlv
product
offer
faster
effect
protect
diseas
shed
virul
viru
challeng
inactiv
vaccin
reason
older
dog
hous
younger
suscept
anim
vaccin
mlv
vaccin
case
outbreak
mlv
vaccin
alway
use
mlv
product
consist
shed
fece
vaccin
dog
infect
contact
anim
may
develop
weak
posit
reaction
fecal
parvoviru
enzymelink
immunosorb
assay
elisa
test
develop
diseas
matern
antibodi
blockad
predomin
reason
parvovir
vaccin
inconsist
protect
pup
primari
vaccin
attenu
inactiv
vaccin
break
matern
immun
effect
virul
canin
parvoviru
overcom
period
matern
antibodi
blockad
manufactur
rais
titer
lower
serial
passag
recommend
use
potent
parvovir
vaccin
complet
seri
begin
week
age
repeat
vaccin
given
everi
week
dog
week
old
despit
fact
product
label
claim
protect
week
age
last
inocul
given
week
age
breed
doberman
pinscher
rottweil
identifi
poorli
respons
cpv
vaccin
absenc
matern
immun
pup
present
week
age
one
mlv
inocul
may
suffici
protect
parvovir
infect
vaccin
mlv
cdv
concurr
vaccin
caus
immunosuppress
observ
coinfect
virul
viru
altern
distemp
parvovir
vaccin
young
puppi
weekli
longer
interv
thu
need
recommend
anim
recov
document
parvovir
infect
recommend
wait
week
vaccin
immun
respons
recov
immun
parvovir
infect
probabl
lifelong
howev
booster
given
conveni
afford
combin
product
great
environment
resist
parvovirus
young
pup
kept
away
park
board
facil
dog
show
vaccin
seri
complet
veterinarian
attempt
limit
suspect
parvovirusinfect
dog
come
contact
suscept
puppi
veterinari
hospit
wait
room
ward
vaccin
cat
felin
panleukopenia
protect
infect
genet
result
antigen
shift
canin
parvoviru
sinc
initi
evolut
nevertheless
crossprotect
still
exist
old
strain
vaccin
new
field
isol
similarli
immunodiagnost
test
base
monoclon
antibodi
origin
isol
still
sensit
detect
newer
strain
viru
newer
field
isol
infect
cat
limit
evid
suggest
vaccin
base
strain
infect
cat
durat
immun
mlv
vaccin
sever
year
least
year
base
challeng
studi
overvaccin
consider
durat
immun
subsequ
administr
inactiv
kill
cpv
product
shown
protect
puppi
challeng
least
month
field
condit
dog
may
partial
protect
weaker
mlv
inactiv
product
yet
still
boost
immun
expos
virul
viru
vaccin
licens
canin
coronaviru
ccv
inactiv
canin
coronavir
felin
coronavir
strain
one
attenu
mlv
canin
coronavir
product
exist
manufactur
recommend
two
dose
vaccin
given
week
apart
begin
puppi
week
age
last
one
given
least
week
age
vaccin
seem
safe
howev
allerg
reaction
may
occur
commonli
inactiv
corona
viral
vaccin
combin
leptospir
bacterin
avoid
potenti
interact
ccv
vaccin
could
use
puppi
week
age
leptospira
vaccin
could
institut
thereaft
otherwis
clinician
may
prefer
decid
whether
import
necessari
product
administ
ccv
challeng
studi
indic
protect
sinc
possibl
produc
experiment
diseas
dog
week
age
furthermor
manufactur
recommend
administ
ccv
booster
vaccin
annual
difficult
justifi
base
fact
ccv
caus
diseas
adult
dog
ccv
produc
significantli
less
morbid
minim
mortal
compar
experiment
combin
infect
ccv
shown
produc
clinic
diseas
sever
either
infect
alon
nevertheless
also
shown
vaccin
cpv
prevent
clinic
diseas
virus
routin
frequent
use
ccv
vaccin
dog
difficult
ration
clinic
infect
typic
occur
puppi
week
age
younger
studi
suggest
durat
qualiti
immun
deriv
natur
exposur
infect
actual
prefer
attempt
immun
way
vaccin
absenc
reliabl
commerci
inhospit
diagnost
assay
ccv
preval
clinic
diseas
associ
ccv
infect
dog
unknown
consid
extrem
low
even
highdens
shelter
environ
yet
ccv
kill
mlv
commerci
incorpor
sever
multival
vaccin
combin
distemp
adenoviru
parainfluenza
viru
parvoviru
antigen
fact
multival
vaccin
contain
ccv
outsel
vaccin
contain
ccv
unit
state
suggest
routin
ccv
inocul
dog
throughout
life
common
ccv
vaccin
consid
among
least
import
vaccin
antigen
given
dog
today
howev
identifi
sever
author
vaccin
quit
simpli
need
leptospir
vaccin
dog
contain
inactiv
serovar
canicola
icterohaemorrhagia
vaccin
product
recommend
anim
less
week
age
allergen
natur
product
leptospira
bacterin
usual
use
reconstitut
lyophil
compon
combin
vaccin
leptospira
bacterin
may
produc
high
level
long
durat
immun
agent
although
postvaccin
titer
often
declin
undetect
level
unpublish
challeng
studi
suggest
immun
dog
sustain
year
inactiv
leptospira
vaccin
may
howev
protect
carrier
state
may
develop
exposur
virul
organ
one
vaccin
manufactur
employ
technolog
involv
separ
surfac
protein
immunogen
leptospira
extran
cellular
debri
therebi
avoid
need
use
wholecel
bacteria
known
whether
technolog
reduc
incid
advers
event
young
dog
toy
breed
recogn
convent
wholecel
bacterin
leptospir
vaccin
consid
option
veterinarian
mani
area
perceiv
low
incid
diseas
short
durat
immun
risk
postvaccin
hypersensit
use
leptospira
vaccin
probabl
respons
reduc
preval
diseas
caus
l
canicola
l
icterohaemorrhagia
recent
shown
incid
confirm
case
canin
leptospirosi
may
increas
unit
state
furthermor
dog
diagnos
infect
serovar
l
interrogan
routin
vaccin
serovar
l
grippotyphosa
l
pomona
l
bratislava
other
report
throughout
unit
state
link
acut
renal
failur
anoth
interest
point
mani
report
dog
live
exclus
urban
area
risk
infect
limit
dog
live
outdoor
rural
environ
vaccin
contain
convent
use
serovar
l
canicola
l
icterohaemorrhagia
crossprotect
serovar
known
infect
dog
less
year
ago
leptospira
vaccin
introduc
believ
protect
serovar
l
grippotyphosa
l
pomona
addit
leptospira
serovar
like
introduc
near
futur
nevertheless
incid
acut
anaphylaxi
among
young
dog
especi
week
age
toy
breed
regardless
age
make
decis
includ
routin
vaccin
dog
avail
leptospira
serovar
difficult
without
region
incid
data
canin
leptospirosi
practition
still
insuffici
inform
dispos
make
reason
riskbenefit
analysi
regard
use
leptospira
vaccin
commerci
inactiv
kill
wholecel
bacterin
one
recombin
outer
surfac
protein
ospa
vaccin
licens
unit
state
europ
vaccin
wholecel
type
vaccin
shown
challeng
studi
conduct
manufactur
recombin
outer
surfac
protein
vaccin
provid
durat
immun
year
vaccin
protect
challeng
dog
spirochetemia
clinic
limp
episod
compar
unvaccin
dog
lyme
borreliosi
vaccin
recommend
manufactur
use
dog
young
week
age
primari
vaccin
consist
two
inocul
week
apart
immun
given
earli
life
highrisk
dog
live
endem
region
note
vaccin
stimul
antibodi
produc
posit
test
result
indirect
fluoresc
antibodi
serodiagnost
test
dog
posit
indirect
fluoresc
antibodi
test
retest
use
either
two
test
western
blot
techniqu
may
discrimin
infect
vaccineinduc
antibodi
recent
introduc
inhospit
elisa
test
snap
assay
idexx
laboratori
westbrook
shown
react
antibodi
uniqu
surfac
peptid
elisa
test
crossreact
antibodi
produc
commerci
avail
vaccin
market
unit
state
claim
hypersensit
induc
wholecel
lyme
vaccin
report
common
observ
postvaccin
lame
among
dog
show
clinic
serolog
evid
infect
unfortun
vaccin
contain
limit
number
strain
may
crossprotect
known
isol
b
burgdorjeri
routin
test
dog
use
inhospit
elisa
test
region
unit
state
lyme
borreliosi
suspect
known
occur
human
be
provid
new
inform
pertain
region
incid
infect
among
canin
popul
today
inform
larg
extrapol
human
incid
data
maintain
center
diseas
control
prevent
meantim
routin
vaccin
dog
b
burgdorjeri
indic
outsid
region
known
high
diseas
preval
infect
protozoan
giardia
lamblia
known
affect
mammal
bird
worldwid
differ
exist
pathogen
host
rang
variou
strain
colon
intestin
lumen
result
intestin
villu
shorten
malabsorpt
diarrhea
neonat
anim
suscept
infect
area
impound
unfilt
surfac
water
use
recreat
drink
often
associ
infect
unsanitari
condit
lead
endem
infect
inactiv
adjuv
vaccin
avail
vaccin
puppi
kitten
first
dose
given
anim
young
week
age
neither
routin
annual
revaccin
indic
product
except
unusu
situat
recurr
exposur
infect
document
control
use
convent
hygien
method
vaccin
shown
diminish
fecal
shed
infecti
cyst
year
vaccin
also
reduc
rate
quantiti
infect
given
exposur
preval
infect
high
group
anim
specif
area
vaccin
might
adjunct
help
control
diseas
recommend
administr
dog
use
must
coupl
manag
procedur
current
vaccin
shown
caus
granulomalik
mass
inocul
site
import
note
accur
identif
giardia
dog
diarrhea
straightforward
may
seem
falseposit
diagnos
giardiasi
probabl
common
convent
salin
fecal
flotat
techniqu
adequ
diagnos
giardia
cyst
fece
furthermor
direct
fecal
examin
limit
experi
microscopist
fact
mani
structur
fece
dog
yeast
bodi
easili
confus
giardia
cyst
fece
subject
centrifug
flotat
zinc
sulfat
solut
slide
scan
x
object
magnif
rabi
vaccin
extrem
effect
reduc
preval
diseas
dog
result
preval
human
diseas
decreas
substanti
although
rel
preval
felin
rabi
increas
unit
state
countri
inactiv
kill
vaccin
use
inactiv
viru
vaccin
shown
provid
minimum
durat
level
immun
compar
mlv
product
often
contain
high
viral
content
potent
adjuv
howev
sometim
produc
acut
chronic
hypersensit
reaction
avipoxvirusvector
recombin
rabi
vaccin
produc
minim
inflammatori
reaction
licens
use
cat
singl
rabi
vaccin
gener
administ
anim
month
age
second
dose
administ
year
first
dose
regardless
dog
age
subsequ
booster
requir
everi
year
thereaft
mandat
state
law
local
statut
new
technolog
vaccin
develop
infecti
diseas
like
introduc
near
futur
new
technolog
come
opportun
vaccin
companion
anim
even
infecti
agent
current
practic
unit
state
today
look
forward
becom
particularli
import
review
current
vaccin
standard
appli
dog
respect
current
knowledg
durat
immun
tabl
awar
incid
likelihood
injuri
even
fatal
advers
event
associ
vaccin
individu
risk
factor
dictat
vaccin
appropri
stage
life
